Opendata, web and dolomites


Assessing the feasibility of MT-011, a first-in-class drug to treat glaucoma and other neurodegenerative diseases via a breakthrough mechanism-of-action

Total Cost €


EC-Contrib. €






 SA-VOIR project word cloud

Explore the words cloud of the SA-VOIR project. It provides you a very rough idea of what is the project "SA-VOIR" about.

inherently    seeing    optimization    house    indicated    de    upfront    biochemical    biotechnological    manner    subtype    candidate    mt    investment    affinity    elucidated    receive    clinical    eye    companies    prominent    sa    enzyme    assets    deterioration    people    proprietary    applicable    documents    30    aside    halt    pharmaceutical    risked    payments    drug    parkinson    licensing    outline    components    peripheral    critical    imminent    implicated    guide    hyperactivated    broad    business    family    diagnosed    trials    inhibits    santen    report    tension    neurogenerative    40m    assay    plan    irreverisble    total    strengthen    drugs    normal    world    inhibit    vision    blindness    applicability    followed    neurodegenerative    molecule    million    diseases    commercialize    small    voir    milestone    attract    pfizer    stage    treatments    nanomolar    alzheimer    glaucoma    pharmaceuticals    vash    patients    dysregulation    newly    black    deal    start    011    size    causes    form    tunnel    continued    disorder    inhibiting    act   

Project "SA-VOIR" data sheet

The following table provides information about the project.


Organization address
address: 66 RUE DU CLAOUS
postcode: 34190
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-12-01   to  2020-05-31


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    MT ACT FR (CAZILHAC) coordinator 50˙000.00


 Project objective

Glaucoma is the world's leading cause of irreverisble blindness, affecting 20 million people in Europe and the US. Known as the Alzheimer’s of the eye, glaucoma is a neurodegenerative disorder that causes deterioration in peripheral vision. Affected patients report ‘seeing through a black tunnel’. Treatments to halt vision loss are available however, they are only applicable for the ‘high tension glaucoma’ subtype. For those diagnosed with ‘normal tension', which comprises over 30% of glaucoma patients, no treatments are available, and vision loss is imminent. New drugs that inhibit VASH, a newly elucidated enzyme that is hyperactivated in many neurogenerative diseases, have potential to address this need.

We at MT-act are a biotechnological start-up who have identified a family of VASH-inhibiting small molecule drugs. Using an in-house proprietary biochemical assay followed by lead optimization, we have identified MT-011, which inhibits VASH with nanomolar affinity, as our lead candidate. Aside from glaucoma, VASH dysregulation is also implicated in other prominent neurodegenerative diseases such as Alzheimer’s and Parkinson’s. Our assets therefore have an inherently broad applicability.

We aim to develop MT-011 up to the stage of Phase 1 clinical trials, upon which we aim to commercialize the drug via a licensing deal with a pharmaceutical partner. We will then receive upfront and milestone payments with a estimated total deal size of €40M. We are currently in discussion with world-leading pharmaceutical companies Pfizer and Santen Pharmaceuticals, who have already indicated interest in our drugs.

In SA-VOIR, we aim to strengthen the business case for MT-011 and to outline a detailed technical plan for its continued development. These documents will not only guide us in developing MT-011 towards Phase 1 trials in an effective and de-risked manner, it will also form critical components of a business plan that we will use to attract further investment.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SA-VOIR" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "SA-VOIR" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

MCBD (2019)


Read More  

In-Heal (2019)

Standardised administration device for raw medical herbs

Read More  

EVERCAM (2020)

Intelligent Vision System for Improved Communication and Higher Productivity in Construction

Read More